Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
暂无分享,去创建一个
M. Carrington | D. Richman | T. O'Brien | D. Havlir | D. McDermott | P. Murphy | David H. McDermott | J. Ioannidis
[1] H. Schuitemaker,et al. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. , 1999, Journal of immunology.
[2] M. Lederman,et al. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. , 1999, JAMA.
[3] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[4] H. Schuitemaker,et al. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS. , 1999, AIDS.
[5] J. Goedert,et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.
[6] J. Goedert,et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.
[7] J. Ioannidis,et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.
[8] C. Kleeberger,et al. CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.
[9] P. O’Connell,et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.
[10] J. Goedert,et al. Genetic effects on HIV disease progression , 1998, Nature Medicine.
[11] J J Goedert,et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.
[12] J J Goedert,et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.
[13] Nancy Sullivan,et al. CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.
[14] M. Carrington,et al. HIV-1 infection in a man homozygous for CCR5 delta 32. , 1997, Lancet.
[15] L. Stuyver,et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene , 1997, Antimicrobial agents and chemotherapy.
[16] D. Weissman,et al. Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.
[17] J J Goedert,et al. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.
[18] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[19] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[20] J. Goedert,et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.
[21] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[22] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[23] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[24] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .